<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        50-968-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        OZAPIN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLANZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Orodispersible tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        265.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1898]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ozapin belongs to a group of medicines called antipsychotics and is used to treat the following</p><p>conditions:</p><p>&bull; Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. People with this disease may also feel depressed, anxious or tense.</p><p>&bull; Moderate to severe manic episodes, a condition with symptoms of excitement or euphoria.</p><p>Ozapin has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Ozapin</strong></p><p>&bull; if you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6).</p><p>An allergic reaction may be recognized as a rash, itching, a swollen face, swollen lips or shortness of breath. If this has happened to you, tell your doctor.</p><p>&bull; If you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before you take Ozapin</p><p>&bull; The use of Ozapin in elderly patients with dementia is not recommended as it may have serious side effects.</p><p>&bull; Medicines of this type may cause unusual movements mainly of the face or tongue. If this happens after you have been given Ozapin tell your doctor.</p><p>&bull; Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. If this happens, contact your doctor at once.</p><p>&bull; Weight gain has been seen in patients taking Ozapin. You and your doctor should check your weight regularly.</p><p>&bull; High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Ozapin. Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Ozapin and regularly during treatment.</p><p>&bull; Tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots.</p><p>If you suffer from any of the following illnesses tell your doctor as soon as possible:</p><p>&bull; Stroke or &ldquo;mini&rdquo; stroke (temporary symptoms of stroke)</p><p>&bull; Parkinson&rsquo;s disease</p><p>&bull; Prostate problems</p><p>&bull; A blocked intestine (Paralytic ileus)</p><p>&bull; Liver or kidney disease</p><p>&bull; Blood disorders</p><p>&bull; Heart disease</p><p>&bull; Diabetes</p><p>&bull; Seizures</p><p>If you suffer from dementia, you or your carer/relative should tell your doctor if you have ever had a stroke or &ldquo;mini&rdquo; stroke.</p><p>As a routine precaution, if you are over 65 years your blood pressure may be monitored by your doctor.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Ozapin is not for patients who are under 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and Ozapin</strong></p><p>Only take other medicines while you are on Ozapin if your doctor tells you that you can. You might feel drowsy if Ozapin is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor if you are taking:</p><p>&bull; Medicines for Parkinson&rsquo;s disease.</p><p>&bull; Carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Ozapin dose.</p><p>&bull; Lithium or valproate (as in either combination with Ozapin may induce some side effects, see section 4 &ldquo;Possible Side Effects&rdquo;).</p><p>&nbsp;</p><p><strong>Ozapin with alcohol</strong></p><p>Do not drink any alcohol if you have been given Ozapin as together with alcohol it may make you feel drowsy.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. You should not be given this medicine when breast-feeding, as small amounts of Ozapin can pass into breast milk.</p><p>The following symptoms may occur in newborn babies, of mothers that have used Ozapin in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>There is a risk of feeling drowsy when you are given Ozapin. If this happens do not drive or operate any tools or machines. Tell your doctor.</p><p>&nbsp;</p><p><strong>Ozapin contains aspartame</strong></p><p>Patients who cannot take phenylalanine should note that Ozapin contains aspartame, which is a source of phenylalanine. May be harmful for people with phenylketonuria.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you.</p><p>Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will tell you how many Ozapin tablets to take and how long you should continue to take them. The daily dose of Ozapin is between 5 and 20 mg.</p><p>Consult your doctor if your symptoms return but do not stop taking Ozapin unless your doctor tells you to.</p><p>You should take your Ozapin tablets once a day following the advice of your doctor. Try to take your tablets at the same time each day. It does not matter whether you take them with or without food.</p><p>Ozapin Oral Disintegrating tablets are for oral use.</p><p>Ozapin tablets break easily, so you should handle the tablets carefully. Do not handle the tablets with wet hands as the tablets may break up.</p><p>1. Keep your hands dry.</p><p>2. Take the tablet carefully out of the pocket</p><p>Put the tablet in your mouth. It will dissolve directly in your mouth, so that it can be easily swallowed. You can also place the tablet in a full glass or cup of water, orange juice, apple juice or milk, and stir. With some drinks, the mixture may change color and possibly become cloudy. Drink it straight away.</p><p>&nbsp;</p><p><strong>If you take more Ozapin than you should</strong></p><p>Patients who have taken more Ozapin than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. Contact your doctor or hospital straight away. Show the doctor your pack of tablets.</p><p>&nbsp;</p><p><strong>If you forget to take Ozapin</strong></p><p>Take your tablets as soon as you remember. Do not take two doses in one day.</p><p>&nbsp;</p><p><strong>If you stop taking Ozapin</strong></p><p>Do not stop taking your tablets just because you feel better. It is important that you carry on taking Ozapin for as long as your doctor tells you.</p><p>If you suddenly stop taking Ozapin, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. Your doctor may suggest you to reduce the dose gradually before stopping treatment.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you have:</p><p>&bull; Unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;</p><p>&bull; Blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately.</p><p>&bull; A combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness (the frequency of this side effect cannot be estimated from the available data).</p><p>Very common side effects (may affect more than 1 in 10 people) include weight gain; sleepiness; and increases in levels of prolactin in the blood.</p><p>In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position. This will usually pass on its own but if it does not, tell your doctor.</p><p>&nbsp;</p><p>Ozapine administered with lithium or valproate resulted in increased levels (&ge;10%) of tremor, dry mouth (32% for olanzapine combination vs 9% for placebo), increased appetite (24% vs 8%), increased salivation (6% vs 2%), weight gain (26% vs 7%), dizziness (14% vs 7%), back pain (8% vs 4%), constipation (8% vs 4%). Speech disorder (7% vs 1%) was also reported commonly, amnesia (5% vs 2%), and paresthesia (5% vs 2%).</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes;</p><p>increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual</p><p>movements (dyskinesias); problems with speech; constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet, fever, joint pain and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasm (including eye movements); spasms of the muscle of the eye causing rolling movement of the eye; problems with speech; slow heart rate; sensitivity to sunlight; bleeding from the nose: abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection.</p><p>&nbsp;</p><p>While taking olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme tiredness, visual hallucinations, a rise in body temperature, redness of the skin and have trouble walking.</p><p>Some fatal cases have been reported in this particular group of patients.</p><p>In patients with Parkinson&rsquo;s disease Ozapin may worsen the symptoms.</p><p>&nbsp;</p><p>Very rare side effects include serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia).</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist.</p><p>This includes any possible side effects not listed in this leaflet.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date, which is stated on the carton.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C. Ozapin should be stored in its original pack in order to protect from light and moisture.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is olanzapine. Each Ozapin Oral Disintegrating tablet contains either 5 mg, 10 mg, 15 mg or 20 mg of the active substance. The exact amount is shown on your Ozapin pack.</p><p>&bull; The other ingredients are: Pearlitol SD 200, Prosolv SMCC 90, Aspartame NF, Hydroxypropyl cellulose Low-S, Crospovidone NF, Colloidal silicon dioxide, Magnesium Stearate</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ozapin 5 mg: A yellow colour, round, flat face, bevelled edge uncoated tablet, engraved with “T40” on one side and plain on the other side.
Ozapin 10 mg: A yellow colour, round, flat face, bevelled edge uncoated tablet, engraved with “T41” on one side and plain on the other side.
Ozapin 15 mg: A yellow colour, round, flat face, bevelled edge uncoated tablet, engraved with “T42” on one side and plain on the other side.
Ozapin 20 mg: A yellow colour, round, flat face, bevelled edge uncoated tablet, engraved with “T43” on one side and plain on the other side.

Ozapin pack contains 30 Oral Disintegrating tablet

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dammam Pharma</p><p>Saudi Arabia</p><p>Address: 1st industrial city, unit No.1, PO.BOX: 7137, Dammam 32234-4384</p><p>Phone: +966138216444</p><p>Fax: +966138216422</p><p>Email:&nbsp;regulatory-affairs@dammampharma.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2019.  
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي أوزابين إلى مجموعة من الأدوية تسمى مضادات الذهان و يستخدم لعلاج الحالات التالية :</p><ul><li dir="RTL">لعلاج مرض الفصام وهو مرض يتسم بالأعراض التالية مثل تخيل سماع أو رؤية أو الإحساس بأشياء غير موجودة، أو اعتقادات خاطئة، أو شكوك غير عادية، و التي قد تصبح انسحابية. و المرضى المصابين بهذا المرض قد يشعرون أيضا بالاكتئاب أو القلق أو التوتر.</li><li dir="RTL">لعلاج نوبات الهوس من المتوسطة إلى الشديدة، و هي حالات مصحوبة بأعراض الهيجان أو النشوة.</li></ul><p>يستخدم أوزابين لمنع تكرار حدوث هذه الأعراض في المرضى المصابين باضطراب ازدواجي القطبية و الذين تستجيب نوبات الهوس لديهم للعلاج بالأولانزابين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أوزابين فى الحالات الآتية:</strong></p><ul><li dir="RTL">إذا كنت تعاني من حساسية (فرط الحساسية) للأولانزابين أو أي من المكونات الأخرى لهذا الدواء (و المذكورة في الفقرة 6). يمكن التعرف على تفاعلات الحساسية والتى قد تظهر فى شكل الحكة أو الطفح الجلدي، أو تورم الوجه و الشفاه أو ضيق في التنفس. إذا حدث لك ذلك فأخبر طبيبك المعالج.</li><li dir="RTL">إذا كان قد تم تشخيصك في وقت سابق بأن لديك مشاكل في العين مثل بعض أنواع الجلوكوما (زيادة ضغط العين)</li></ul><p dir="RTL"><strong>تحذيرات و احتياطات:</strong></p><p dir="RTL">تحدث مع طبيبك المعالج أو الصيدلي قبل تناول أوزابين.</p><ul><li dir="RTL">لا يوصى بإعطاء أوزابين لكبار السن المصابين بالخرف لأنه قد يسبب آثار جانبية خطيرة.</li><li dir="RTL">الأدوية من هذا النوع قد تسبب حركات غير عادية غالباً ما تكون في الوجه أو اللسان. إذا حدث هذا لك بعد تناول أوزابين فعليك إخبار الطبيب.</li><li dir="RTL">في حالات نادرة جدا، هذا النوع من الأدوية يؤدي إلى مزيج من ارتفاع درجة الحرارة و سرعة التنفس، و التعرق ، و تصلب العضلات، و الدوار أو النعاس. إذا حدث هذا لك، فاتصل بطبيبك على الفور.</li><li dir="RTL">لوحظ زيادة الوزن في المرضى الذين يتناولون أوزابين. لذلك يجب عليك وعلى طبيبك المعالج متابعة وزنك بانتظام.</li><li dir="RTL">لوحظ ارتفاع مستوى السكر في الدم و ارتفاع مستويات الدهون ( الدهون الثلاثية و الكوليسترول) في المرضى الذين يتناولون أوزابين. و على طبيبك أن يجري لك فحوصات الدم للكشف عن مستوى السكر في الدم و بعض مستويات الدهون قبل البدء بتناول أوزابين و بانتظام أثناء تناوله.</li><li dir="RTL">أخبر طبيبك المعالج لو أنك أو أي شخص من العائلة لديه تاريخ مسبق للإصابة بجلطة دموية، حيث أن تناول هذه النوعية من الأدوية قد يصاحبه تكوين جلطات دموية.</li></ul><p dir="RTL">إذا كنت تعاني من أي من الأمراض التالية أخبر طبيبك في أقرب وقت ممكن:</p><ul><li dir="RTL">السكتة الدماغية أو السكتة الدماغية &quot;المصغرة&quot; (أعراض مؤقتة للسكتة الدماغية)</li><li dir="RTL">مرض باركنسون</li><li dir="RTL">انسداد الأمعاء (العلوص المشلول)</li><li dir="RTL">أمراض الكبد و الكلى</li><li dir="RTL">اضطرابات الدم</li><li dir="RTL">مرض القلب</li><li dir="RTL">مرض السكري</li><li dir="RTL">تشنجات</li></ul><p dir="RTL">إذا كنت تعاني من الخرف فيجب عليك أو على من يقدم لك الرعاية/ أحد أقربائك إخبار الطبيب إذا كنت مصابا أو قد تعرضت مسبقاً لسكتة دماغية أو سكتة دماغية (مصغرة)</p><p dir="RTL">كإجراء وقائي روتيني، إذا كنت أكثر فى العمر من 65 عاماً سيتم رصد ضغط الدم لديك من قبل الطبيب.</p><p dir="RTL"><strong>الأطفال و المراهقين</strong></p><p dir="RTL">لا يستخدم أوزابين من قبل المرضى الذين تقل أعمارهم عن 18 عاماً.</p><p dir="RTL"><strong>تناول أدوية أخرى مع أوزابين</strong></p><p dir="RTL">بإمكانك تناول أدوية أخرى أثناء تناولك لأوزابين فقط إذا سمح لك الطبيب بذلك . قد تشعر بالنعاس إذا تناولت أوزابين بالاشتراك مع مضادات الاكتئاب أو مع الأوية التي تؤخذ للقلق أو لمساعدتك على النوم (المهدئات)</p><p dir="RTL">يرجى إخبار الطبيب إذا كنت تتناول، أو تناولت في الآونة الأخيرة أي أدوية أخرى.</p><p dir="RTL">أخبر طبيبك خاصةً إذا كنت تتناول:</p><ul><li dir="RTL">أدوية لمرض باركنسون.</li><li dir="RTL">كاربامازيبين (مصاد للصرع و مثبت للمزاج)، فلوفوكسامين (مضاد للاكتئاب) أو سيبروفلوكساسين (مضاد حيوي)، حيث قد يكون من الضروري تغيير جرعة أوزابين الخاصة بك.</li><li dir="RTL">الليثيوم أو فالبروات (حيث أن الجمع بين أي من هذين الدوائين مع أوزابين قد يسبب بعض الأعراض الجانبية، انظر فقرة 4 &quot;الأعراض الجانبية المحتملة&quot;).</li></ul><p dir="RTL"><strong>تناول أوزابين مع الكحول</strong></p><p dir="RTL">يجب تجنب شرب أي نوع من الكحول إذا تم وصف أوزابين لك، حيث أن تناول أوزابين مع الكحول معاً قد يجعلك تشعر بالنعاس.</p><p dir="RTL"><strong>الحمل و الرضاعة</strong></p><p dir="RTL">إذا كنت حاملاً أو ترضعين طفلك طبيعياً، أو تعتقدين أنك قد تكونين حاملاً أو تخططين للحمل، فاستشيري طبيبك المعالج قبل تناول هذا الدواء. يجب ألا يعطى هذا الدواء عند الرضاعة من الثدي، حيث أن كميات قليلة من أوزابين يمكن أن تنتقل عبر حليب الثدي.</p><p dir="RTL">قد تظهر هذه الأعراض لدى المواليد، لأمهات استخدمن أوزابين في الثلث الأخير (الأشهر الثلاثة الأخيرة من الحمل): رعشة، تيبس و/ أو ضعف العضلات، نعاس، هيجان، مشاكل في التنفس، و صعوبة في التغذية. إذا أصيب طفلك بأي من هذه الأعراض فقد يلزمك التواصل مع طبيبك المعالج.</p><p dir="RTL"><strong>قيادة السيارات و استخدام الآلات</strong></p><p dir="RTL">قد تكون هناك خطورة من الشعور بالنعاس عند تناولك لأوزابين، إذا حدث لك ذلك فلا تقم بالقيادة أو تشغيل الآلات. أخبر طبيبك المعالج.</p><p dir="RTL"><strong>أوزابين يحتوى على أسبارتام: </strong></p><p dir="RTL">يجب على المرضى الغير قادرين على تناول فينيل ألانين الأخذ بالاعتبار أن أقراص أوزابين تحتوى على أسبارتام، وهو مصدر فينيل ألانين. مما قد يسبب ضرراً للناس المصابين ببيلة الفينيل كيتون.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائما هذا الدواء تماما كما وصف لك طبيبك. يجب عليك أن تستشير طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">سوف يخبرك طبيبك المعالج بعدد الأقراص التى يجب عليك أن تتناولها من أوزابين و المدة الزمنية التي ينبغي أن تستمر عليها. تتراوح الجرعة اليومية من أوزابين ما بين 5 إلى 20 ملجم. استشِر طبيبك المعالج إذا ظهرت لديك الأعراض مرة أخرى و لكن لا تتوقف عن تناول أوزابين مالم يطلب منك الطبيب ذلك.</p><p dir="RTL">يجب أن تتناول أقراص أوزابين الخاصة بك مرة واحدة في اليوم حسب نصيحة الطبيب. حاول أن تتناول أقراصك في نفس الوقت من كل يوم. لا يهم ما إذا كنت تتناولها مع أو بدون الطعام.</p><p dir="RTL">أقراص أوزابين القابلة للانتشار<strong> </strong>بالفم مهيأة للاستخدام عن طريق الفم.</p><p dir="RTL">أقراص أوزابين معرضة بسهولة للكسر، لذلك يجب عليك التعامل معها بحرص. لا تتعامل مع الأقراص بأيدٍ مبللة حيث قد تعرض القرص للكسر.</p><p dir="RTL">1. احرص على جفاف يدك.</p><p dir="RTL">2. قم بإخراج القرص من الشريط بحرص.</p><p dir="RTL">ضع القرص فى فمك. سوف يذوب مباشرةً فى فمك، مما يسهل عليك ابتلاعه. يمكنك أيضاً وضع القرص فى كوب من الماء أو عصير البرتقال أو عصير التفاح أو اللبن مع التقليب. مع بعض المشروبات قد يتغير اللون وقد يصبح عكراً. قم بشربه فى الحال.</p><p dir="RTL"><strong>إذا تناولت أكثر مما يجب من أوزابين</strong></p><p dir="RTL">المرضى الذين تناولوا أكثر مما ينبغي من أوزابين ظهرت لديهم الأعرض التالية: تسارع ضربات القلب، و الإثارة/ العدوانية، مشاكل في الكلام، و حركات غير عادية (لا سيما في الوجه أو اللسان)، و انخفاض مستوى الوعي. قد تظهر أعراض أخرى: الارتباك الحاد، تشنجات (الصرع) و الغيبوبة، مزيج من الحمى، و سرعة في التنفس، تعرق، تصلب العضلات، دوار أو نعاس، تباطؤ في معدل التنفس، و ارتشاف، و ارتفاع أو انخفاض فى ضغط الدم، و إيقاعات غير طبيعية للقلب. عليك الاتصال بالطبيب أو المستشفى على الفور إذا ظهرت عليك أي من الأعراض السابقة. أظهر لطبيبك عبوة الأقراص الخاصة بك.</p><p dir="RTL"><strong>إذا نسيت أن تتناول أوزابين</strong></p><p dir="RTL">تناول أقراصك في أقرب وقت حالما تتذكر. لا تتناول جرعتين في اليوم الواحد.</p><p dir="RTL"><strong>إذا</strong> <strong>توقفت عن تناول أوزابين</strong></p><p dir="RTL">لا تتوقف عن تناول الأقراص الخاصة بك فقط لأنك تشعر بتحسن. فمن المهم أن تستمر بتناول أوزابين طوال الفترة التي يطلبها الطبيب منك.</p><p dir="RTL">إذا توقفت فجأة عن تناول أوزابين، فقد تظهر لديك أعراض مثل التعرق، عدم القدرة على النوم، رعشة، قلق أو غثيان أو قيء. قد يقترح عليك طبيبك تقليل الجرعة تدريجياً قبل وقف العلاج.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فأسأل طبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب أوزابين أعراضاً جانبية، على الرغم من أنها قد لا تحدث لدى الجميع.</p><p dir="RTL">أخبر طبيبك المعالج فى الحال إذا تعرضت لأى مما يلى:</p><ul><li dir="RTL">حركة غير عادية ( من الآثار الجانبية الشائعة التي قد تؤثر على ما يصل إلى 1 من بين 10 أشخاص) و غالباً ما تكون في الوجه أو اللسان.</li><li dir="RTL">جلطات الدم في الأوردة (تأثير جانبي غير شائع و الذي قد يؤثر على ما يصل إلى 1 من بين 100 شخص) و خاصةً في الساقين (تتضمن الأعراض تورم، و ألم ، و احمرار في الساق)، و التي قد تنتقل عبر الأوعية الدموية إلى الرئتين مما يسبب ألم في الصدر و صعوبة في التنفس. إذا لاحظت أي من هذه الأعراض فاطلب المشورة الطبية على الفور.</li><li dir="RTL">مزيج من الحمى ، و سرعة في التنفس ، التعرق، تصلب العضلات و الدوار أو النعاس ( لا يمكن تقدير تكرارية هذه الآثار الجانبية من البيانات المتاحة).</li></ul><p dir="RTL">الآثار الجانبية الشائعة جدا (قد تؤثر في أكثر من 1 لكل 10 مستخدمين) و تشمل زيادة الوزن، النعاس، زيادة في مستويات البرولاكتين في الدم.</p><p dir="RTL">في المراحل الأولى من العلاج، بعض الأشخاص يمكن أن يشعروا بدوخة أو إغماء ( مع تباطؤ في معدل ضربات القلب) خاصة عند النهوض من وضع الاستلقاء أو الجلوس. و قد يختفي هذا الأثر من تلقاء نفسه و لكن إذا استمر، فأخبر طبيبك المعالج.</p><p dir="RTL">أشارت بعض الدراسات أن استخدام أوزابين بالتزامن مع ليثيوم أو فالبروات أدى إلى زيادة في معدل حدوث الرعشات (&ge; 10٪), جفاف الفم (32٪ في حالة استخدام أوزابين بالتزامن مع ليثيوم أو فالبروات مقابل 9٪ مقارنة مع العلاج الوهمي), زيادة الشهية (24٪ مقابل 8٪)، زيادة إفراز اللعاب (٪6 مقابل 2٪)، زيادة الوزن (26 ٪ مقابل 7 ٪)، الدوخة (14 ٪ مقابل 7 ٪)، ألم الظهر (8 ٪ مقابل 4 ٪)، إمساك (8 ٪ مقابل 4 ٪). تم الإبلاغ أيضاً بشكل شائع عن اضطراب الكلام (٪7 مقابل 1٪)، فقدان الذاكرة (5٪ مقابل 2٪)، والإحساس بوخز (5٪ مقابل 2٪). &nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة (قد تؤثر في 1-10 مستخدمين) و تشمل التغيرات في مستويات بعض خلايا الدم و الدهون المنتشرة في مراحل العلاج الأولى، زيادة مؤقتة في إنزيمات الكبد، زيادة في مستوى السكر في الدم و البول، زيادة في مستوى حمض اليوريك و فسفور الكيرياتين في الدم، الشعور أكثر بالجوع، الدوخة، الأرق، رعشة، حركات غير عادية (خلل في الحركة)، مشاكل في الكلام، إمساك، جفاف الفم، طفح، فقدان القوة، تعب شديد، احتباس للسوائل مما يؤدي إلى تورم اليدين أو الكاحلين أو القدمين، حمى وألم بالمفاصل وقصور جنسي مثل انخفاض الرغبة الجنسية لدى الذكور و الإناث أو عدم القدرة على الانتصاب عند الذكور.</p><p dir="RTL">الآثار الجانبية الغير شائعة ( قد تؤثر في 1 من بين 100 مستخدم) تشمل رد فعل تحسسي (على سبيل المثال تورم في الفم و الحلق، حكة و الطفح الجلدي) مرض السكري أو تفاقم مرض السكري، و أحيانا يتصاحب مع الحماض الكيتوني (الكيتونات في الدم و البول) أو الغيبوبة، تشنجات و ترتبط عادة مع تاريخ مسبق للاصابة بالتشنجات (الصرع)، تشنجات في عضلات العين يسبب حركة دورانية في العين، مشاكل في الكلام، تباطؤ في معدل نبضات القلب، الحساسية للضوء، نزيف من الأنف (الرعاف)، انتفاخ البطن، فقدان الذاكرة أو النسيان، سلس البول، عدم القدرة على التبول،تساقط الشعر، غياب أو نقصان في فترات الطمث، التغيرات في الثدي عند الذكور و الإناث مثل زيادة افراز الحليب بصورة غير طبيعية من الثدي أو نمو غير طبيعي في الثدي.</p><p dir="RTL">الآثار الجانبية النادرة (قد تؤثر في 1 من بين 1000 مستخدم) تشمل انخفاض في درجة حرارة الجسم الطبيعية، ايقاعات شاذة في القلب ،الوفاة المفاجئة غير المبررة، التهاب في البنكرياس مما يسبب آلام حادة في المعدة، حمى و إعياء، مرض الكبد يظهر على هيئة اصفرار الجلد و اصفرار الجزء الأبيض من العينين، مرض في العضلات على هيئة أوجاع و آلام غير مبررة، فترات طويلة من الانتصاب و /أو انتصاب مؤلم.</p><p dir="RTL">أثناء تناول عقار أولانزابين، قد يعاني المرضى المسنين المصابين بالخرف من السكتة الدماغية، الالتهاب الرئوي، و سلس البول، السقوط، و التعب الشديد، و الهلوسة البصرية، و ارتفاع في درجة حرارة الجسم و احمرار في الجلد و صعوبة في المشي. و قد تم الإبلاغ عن بعض حالات الوفاة خاصة في هذه الفئة من المرضى.</p><p dir="RTL">بالنسبة لمرضى الباركنسون قد يؤدي أوزابين إلى تفاقم الأعراض.</p><p dir="RTL">الأعراض الجانبية النادرة جدا تشمل تفاعلات تحسسية خطيرة مثل التفاعلات الدوائية المصاحب لها فرط الحمضات والأعراض الجهازية (متلازمة دريس). تظهر متلازمة دريس في البداية كأعراض تشبه أعراض الأنفلونزا مع طفح جلدي على الوجه ثم ينتشر الطفح الجلدي ، وارتفاع في درجة الحرارة ، وتضخم العقد الليمفاوية ، وزيادة مستويات إنزيمات الكبد في اختبارات الدم وزيادة في نوع من خلايا الدم البيضاء (فرط الحمضات) .</p><p dir="RTL">إذا ظهر لديك أي أثر جانبي فأخبر طبيبك أو الصيدلى . و هذا يشمل أي أثر جانبي ليس مدرجاً في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن نظر ومتناول الأطفال.</p><p dir="RTL">لا تقم بتناول هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة.</p><p dir="RTL">لا يحفظ فى درجة حرارة أعلى من 30 درجة مئوية. يجب حفظ أقراص أوزابين فى العبوة الأصلية لحمايتها من الضوء والرطوبة.</p><p dir="RTL">يجب عدم التخلص من الأدوية عبر النفايات المنزلية أو مياه الصرف الصحى. اسأل الصيدلى بشأن كيفية التخلص من الأدوية التى لم تعد بحاجة إليها. سوف تساعد هذا التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات أقراص أوزابين</strong></p><ul><li dir="RTL">المادة الفعالة هى أولانزابين. يحتوى كل قرص قابل للانتشار<strong> </strong>بالفم من أوزابين على 5 ملجم أو 10 ملجم أو 15 ملجم أو 20 ملجم من المادة الفعالة. الكمية المحددة من المادة الفعالة موضحة على العبوة الخارجية.</li><li dir="RTL">مكونات أخرى وهى: بيرليتول SD 200، بروسولف SMCC 90، أسبارتام NF، هيدروكسى بروبيل سيليولوز S، كروسبوفيدون NF، ثانى أكسيد سيليكون غروى، ستيارات مغنسيوم.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أوزابين 5 ملجم: أقراص غير مغلفة صفراء اللون، مستديرة، ذات وجه مسطح، مشطوفة الحافة، محفور عليها &quot;T40&quot; على أحد الجانبين و عادية على السطح الآخر.</p><p dir="RTL">أوزابين 10 ملجم: أقراص غير مغلفة صفراء اللون، مستديرة، ذات وجه مسطح، مشطوفة الحافة، محفور عليها &quot;T41&quot; على أحد الجانبين و عادية على السطح الآخر.</p><p dir="RTL">أوزابين 15 ملجم: أقراص غير مغلفة صفراء اللون، مستديرة، ذات وجه مسطح، مشطوفة الحافة، محفور عليها &quot;T42&quot; على أحد الجانبين و عادية على السطح الآخر.</p><p dir="RTL">أوزابين 20 ملجم: أقراص غير مغلفة صفراء اللون، مستديرة، ذات وجه مسطح، مشطوفة الحافة، محفور عليها &quot;T43&quot; على أحد الجانبين و عادية على السطح الآخر.</p><p dir="RTL">تحتوى كل عبوة من أوزابين على 30 قرص قابل للانتشار بالفم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الدمام فارما</strong></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">المنطقة الصناعية الأولى, وحدة رقم 1, ص.ب: 7137, الدمام 32234-4384</p><p dir="RTL">ت: +966138216444</p><p dir="RTL">فاكس: +966138216422</p><p dir="RTL">البريد الإلكتروني: regulatory-affairs@dammampharma.sa</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2019            
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ozapin 5 mg Oral Disintegrating tablets
Ozapin 10 mg Oral Disintegrating tablets
Ozapin 15 mg Oral Disintegrating tablets
Ozapin 20 mg Oral Disintegrating tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ozapin 5 mg Oral Disintegrating tablets: Each Oral Disintegrating tablet contains 5 mg olanzapine. 
Ozapin 10 mg Oral Disintegrating tablets: Each Oral Disintegrating tablet contains 10 mg olanzapine. 
Ozapin 15 mg Oral Disintegrating tablets: Each Oral Disintegrating tablet contains 15 mg olanzapine. 
Ozapin 20 mg Oral Disintegrating tablets: Each Oral Disintegrating tablet contains 20 mg olanzapine. 
Excipients with known effect: 
Ozapin 5 mg: Each Oral Disintegrating tablet contains 1.00 mg aspartame NF. 
Ozapin 10 mg: Each Oral Disintegrating tablet contains 2.00 mg aspartame NF. 
Ozapin 15 mg: Each Oral Disintegrating tablet contains 3.00 mg aspartame NF. 
Ozapin 20 mg: Each Oral Disintegrating tablet contains 4.00 mg aspartame NF. 
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral Disintegrating tablets 
A yellow colour, round, flat face, bevelled edge uncoated tablet, plain on both sides.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Adults</u></em></p><p>Ozapin is indicated for the treatment of schizophrenia.</p><p>Ozapin is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.</p><p>Ozapin is indicated for the treatment of moderate to severe manic episode.</p><p>In patients whose manic episode has responded to Ozapin treatment, Ozapin is indicated for the prevention of recurrence in patients with bipolar disorder (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><em><u>Adults</u></em></p><p>Schizophrenia: The recommended starting dose for Ozapin is 10 mg/day.</p><p>Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1).</p><p>Preventing recurrence in bipolar disorder: The recommended starting dose is 10 mg/day. For patients who have been receiving Ozapin for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, Ozapin treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.</p><p>During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5- 20 mg/day. An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours.</p><p>Ozapin can be given without regards for meals as absorption is not affected by food. Gradual tapering of the dose should be considered when discontinuing Ozapin.</p><p>Ozapin Oral Disintegrating tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed. Removal of the intact Oral Disintegrating tablet from the mouth is difficult. Since the Oral Disintegrating tablet is fragile, it should be taken immediately on opening the blister. Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration.</p><p><em><u>Paediatric population</u></em></p><p>Olanzapine is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy. A greater magnitude of weight gain, lipid and prolactin alterations has been reported in short term studies of adolescent patients than in studies of adult patients (see sections 4.4, 4.8, 5.1 and 5.2).</p><p><em><u>Elderly patients</u></em></p><p>A lower starting dose (5 mg/day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see section 4.4).</p><p><em><u>Patients with renal and/or hepatic impairment</u></em></p><p>A lower starting dose (5 mg) should be considered for such patients. In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5 mg and only increased with caution.</p><p><em><u>Gender</u></em></p><p>The starting dose and dose range need not be routinely altered for female patients relative to male patients.</p><p><em><u>Smokers</u></em></p><p>The starting dose and dose range need not be routinely altered for non-smokers relative to smokers.</p><p>When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the starting dose. Dose escalation, when indicated, should be conservative in such patients.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients, listed in section 6.1. Patients with known risk of narrow-angle glaucoma. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days to some weeks. Patients should be closely monitored during this period.</p><p><em><u>Dementia-related psychosis and/or behavioural disturbances</u></em></p><p>Olanzapine is not approved for the treatment of dementia-related psychosis and/or behavioural disturbances and is not recommended for use in this particular group of patients because of an increase in mortality and the risk of cerebrovascular accident. In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5% vs. 1.5%, respectively). The higher incidence of death was not associated with olanzapine dose (mean daily dose 4.4 mg) or duration of treatment. Risk factors that may predispose this patient population to increased mortality include age &gt; 65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e.g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines. However, the incidence of death was higher in olanzapine-treated than in placebo-treated patients independent of these risk factors.</p><p>In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported. There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively). All olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors. Age &gt; 75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment. The efficacy of olanzapine was not established in these trials.</p><p><em><u>Parkinson&#39;s disease</u></em></p><p>The use of olanzapine in the treatment of dopamine agonist associated psychosis in patients with Parkinson&#39;s disease is not recommended. In clinical trials, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo (see section 4.8), and olanzapine was not more effective than placebo in the treatment of psychotic symptoms. In these trials, patients were initially required to be stable on the lowest effective dose of anti- Parkinsonian medicinal products (dopamine agonist) and to remain on the same anti-Parkinsonian medicinal products and dosages throughout the study. Olanzapine was started at 2.5 mg/day and titrated to a maximum of 15 mg/day based on investigator judgement.</p><p><em><u>Neuroleptic Malignant Syndrome (NMS)</u></em></p><p>NMS is a potentially life-threatening condition associated with antipsychotic medicinal product. Rare cases reported as NMS have also been received in association with olanzapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicines, including olanzapine must be discontinued.</p><p><em><u>Hyperglycaemia and diabetes</u></em></p><p>Hyperglycaemia and/or development or exacerbation of diabetes occasionally associated with ketoacidosis or coma has been reported rarely, including some fatal cases (see section 4.8). In some cases, a prior increase in body weight has been reported which may be a predisposing factor. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines, e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter. Patients treated with any antipsychotic agents, including Olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control. Weight should be monitored regularly, e.g. at baseline, 4, 8 and 12 weeks after starting olanzapine treatment and quarterly thereafter.</p><p><em><u>Lipid alterations</u></em></p><p>Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo- controlled clinical trials (see section 4.8). Lipid alterations should be managed as clinically appropriate, particularly in dyslipidemic patients and in patients with risk factors for the development of lipids disorders. Patients treated with any antipsychotic agents, including Olanzapine, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.</p><p><em><u>Anticholinergic activity</u></em></p><p>While olanzapine demonstrated anticholinergic activity <em>in vitro</em>, experience during the clinical trials revealed a low incidence of related events. However, as clinical experience with olanzapine in patients with concomitant illness is limited, caution is advised when prescribing for patients with prostatic hypertrophy, or paralytic ileus and related conditions.</p><p><em><u>Hepatic function</u></em></p><p>Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment. Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines. In cases where hepatitis (including hepatocellular, cholestatic or mixed liver injury) has been diagnosed, olanzapine treatment should be discontinued.</p><p><em><u>Neutropenia</u></em></p><p>Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease. Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly (see section 4.8).</p><p><em><u>Discontinuation of treatment</u></em></p><p>Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported very rarely (&lt; 0.01%) when olanzapine is stopped abruptly.</p><p><em><u>QT interval</u></em></p><p>In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] &ge; 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF&lt; 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo. However, as with other antipsychotics, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia.</p><p><em><u>Thromboembolism</u></em></p><p>Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (&ge; 0.1% and &lt; 1%). A causal relationship between the occurrence of venous thromboembolism and treatment with olanzapine has not been established. However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of VTE e.g. immobilisation of patients should be identified and preventive measures undertaken.</p><p><em><u>General CNS activity</u></em></p><p>Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol. As it exhibits <em>in vitro </em>dopamine antagonism, olanzapine may antagonize the effects of direct and indirect dopamine agonists.</p><p>&nbsp;</p><p><em><u>Seizures</u></em></p><p>Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors which may lower the seizure threshold. Seizures have been reported to occur rarely in patients when treated with olanzapine. In most of these cases, a history of seizures or risk factors for seizures were reported.</p><p><em><u>Tardive Dyskinesia</u></em></p><p>In comparator studies of one year or less duration, olanzapine was associated with a statistically significant lower incidence of treatment emergent dyskinesia. However the risk of tardive dyskinesia increases with long term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered. These symptoms can temporally deteriorate or even arise after discontinuation of treatment.</p><p><em><u>Postural hypotension</u></em></p><p>Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials. As with other antipsychotics, it is recommended that blood pressure is measured periodically in patients over 65 years.</p><p><em><u>Sudden cardiac death</u></em></p><p>In postmarketing reports with olanzapine, the event of sudden cardiac death has been reported in patients with olanzapine. In a retrospective observational cohort study, the risk of presumed sudden cardiac death in patients treated with olanzapine was approximately twice the risk in patients not using antipsychotics. In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.</p><p><em><u>Paediatric population</u></em></p><p>Olanzapine is not indicated for use in the treatment of children and adolescents. Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels. Long-term outcomes associated with these events have not been studied and remain unknown (see sections 4.8 and 5.1).</p><p><em><u>Phenylalanine</u></em></p><p>Ozapin Oral Disintegrating tablet contains aspartame, which is a source of phenylalanine. May be harmful for people with phenylketonuria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Paediatric population</u></em></p><p>Interaction studies have only been performed in adults.</p><p><em><u>Potential interactions affecting olanzapine</u></em></p><p>Since olanzapine is metabolised by CYP1A2, substances that can specifically induce or inhibit this isoenzyme may affect the pharmacokinetics of olanzapine.</p><p><em><u>Induction of CYP1A2</u></em></p><p>The metabolism of olanzapine may be induced by smoking and carbamazepine, which may lead to reduced olanzapine concentrations. Only slight to moderate increase in olanzapine clearance has been observed. The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.2).</p><p><em><u>Inhibition of CYP1A2</u></em></p><p>Fluvoxamine, a specific CYP1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine. The mean increase in olanzapine C<sub>max</sub> following fluvoxamine was 54 % in female non- smokers and 77 % in male smokers. The mean increase in olanzapine AUC was 52 % and 108 % respectively. A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin. A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.</p><p><em><u>Decreased bioavailability</u></em></p><p>Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60% and should be taken at least 2 hours before or after olanzapine.</p><p>Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.</p><p><em><u>Potential for olanzapine to affect other medicinal products</u></em></p><p>Olanzapine may antagonise the effects of direct and indirect dopamine agonists.</p><p>Olanzapine does not inhibit the main CYP450 isoenzymes <em>in vitro </em>(e.g. 1A2, 2D6, 2C9, 2C19, 3A4). Thus no particular interaction is expected as verified through <em>in vivo </em>studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and 2C19).</p><p>Olanzapine showed no interaction when co-administered with lithium or biperiden.</p><p>Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.</p><p><em><u>General CNS activity</u></em></p><p>Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.</p><p>The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson&#39;s disease and dementia is not recommended (see section 4.4).</p><p><em><u>QTc interval</u></em></p><p>Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Pregnancy category C.</p><p>There are no adequate and well-controlled studies in pregnant women. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with olanzapine. Nevertheless, because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>Neonates exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p>Breast-feeding</p><p>In a study in breast feeding, healthy women, olanzapine was excreted in breast milk. Mean infant exposure (mg/kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/kg). Patients should be advised not to breast feed an infant if they are taking olanzapine.</p><p>Fertility&nbsp;</p><p>Effects on fertility are unknown</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>Adults</u></p><p>The most frequently (seen in &ge; 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following table lists the adverse reactions and laboratory investigations observed from spontaneous reporting and in clinical trials. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The frequency terms listed are defined as follows: Very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the data available).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Eosinophilia</p><p>Leukopenia<sup>10</sup></p><p>Neutropenia<sup>10</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopenia<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Weight gain<sup>1</sup></p></td><td style="vertical-align:top"><p>Elevated cholesterol levels<sup>2,3</sup></p><p>Elevated glucose levels<sup>4</sup></p><p>Elevated triglyceride levels<sup>2,5</sup></p><p>Glucosuria</p><p>Increased appetite</p></td><td style="vertical-align:top"><p>Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4)<sup>11</sup></p></td><td style="vertical-align:top"><p>Hypothermia<sup>12</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Akathisia<sup>6</sup></p><p>Parkinsonism<sup>6</sup></p><p>Dyskinesia<sup>6</sup></p></td><td style="vertical-align:top"><p>Seizures where in most cases a history of seizures or risk factors for seizures were reported&nbsp;<sup>11</sup></p><p>Dystonia (including oculogyration)<sup>&nbsp;11</sup></p><p>Tardive dyskinesia<sup>11</sup></p><p>Amnesia&nbsp;<sup>9</sup></p><p>Dysarthria</p><p>Stuttering<sup>11</sup></p><p>Restless Legs Syndrome</p></td><td style="vertical-align:top"><p>Neuroleptic malignant syndrome (see section 4.4)&nbsp;<sup>12</sup></p><p>Discontinuation symptoms<sup>7, 12</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bradycardia</p><p>QTc prolongation (see section 4.4)</p></td><td style="vertical-align:top"><p>Ventricular tachycardia/ fibrillation, sudden death (see section 4.4)<sup>&nbsp;11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension<sup>10</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thromboembolism (including pulmonary embolism and deep vein thrombosis) (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Epistaxis<sup>9</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Mild, transient anticholinergic effects including constipation and dry mouth</p></td><td style="vertical-align:top"><p>Abdominal distension<sup>9</sup></p></td><td style="vertical-align:top"><p>Pancreatitis<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatitis (including hepatocellular, cholestatic or mixed liver injury)<sup>&nbsp;11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Photosensitivity reaction</p><p>Alopecia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia<sup>9</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Urinary incontinence, urinary retention</p><p>Urinary hesitation<sup>11</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Pregnancy, puerperium and perinatal conditions</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Erectile dysfunction in males</p><p>Decreased libido in males and females</p></td><td style="vertical-align:top"><p>Amenorrhea</p><p>Breast enlargement</p><p>Galactorrhea in females</p><p>Gynaecomastia/breast enlargement in males</p></td><td style="vertical-align:top"><p>Priapism<sup>12</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthenia</p><p>Fatigue</p><p>Oedema</p><p>Pyrexia<sup>10</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Elevated plasma prolactin levels<sup>8</sup></p></td><td style="vertical-align:top"><p>Increased alkaline phosphatase<sup>10</sup></p><p>High creatine phosphokinase<sup>11</sup></p><p>High Gamma Glutamyltransferase<sup>10</sup></p><p>High uric acid&nbsp;<sup>10</sup></p></td><td style="vertical-align:top"><p>Increased total bilirubin</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>1</sup>Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Following short-term treatment (median duration 47 days), weight gain &ge; 7% of baseline body weight was very common (22.2%); &ge; 15% was common (4.2%); and &ge; 25% was uncommon (0.8%). Patients gaining &ge; 7%, &ge; 15% and &ge; 25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4%, 31.7% and 12.3% respectively).</p><p><sup>2</sup>Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.</p><p><sup>3</sup>Observed for fasting normal levels at baseline (&lt; 5.17 mmol/l) which increased to high (&ge; 6.2 mmol/l). Changes in total fasting cholesterol levels from borderline at baseline (&ge; 5.17 - &lt; 6.2 mmol/l) to high (&ge; 6.2 mmol/l) were very common.</p><p><sup>4</sup>Observed for fasting normal levels at baseline (&lt; 5.56 mmol/l) which increased to high (&ge; 7 mmol/l). Changes in fasting glucose from borderline at baseline (&ge; 5.56 - &lt; 7 mmol/l) to high (&ge; 7 mmol/l) were very common.</p><p><sup>5</sup>Observed for fasting normal levels at baseline (&lt; 1.69 mmol/l) which increased to high (&ge; 2.26 mmol/l). Changes in fasting triglycerides from borderline at baseline (&ge; 1.69 mmol/l - &lt; 2.26 mmol/l) to high (&ge; 2.26 mmol/l) were very common.</p><p><sup>6</sup>In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo. Olanzapine-treated patients had a lower incidence of Parkinsonism, akathisia and dystonia compared with titrated doses of haloperidol. In the absence of detailed information on the pre-existing history of individual acute and tardive extrapyramidal movement disorders, it cannot be concluded at present that olanzapine produces less tardive dyskinesia and/or other tardive extrapyramidal syndromes.</p><p><sup>7</sup>Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly.</p><p><sup>8</sup>&nbsp;In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine-treated patients with normal baseline prolactin value. In the majority of these patients the elevations were generally mild, and remained below two times the upper limit of normal range.</p><p><sup>9</sup>&nbsp;Adverse event identified from clinical trials in the Olanzapine Integrated Database.</p><p><sup>10</sup>&nbsp;As assessed by measured values from clinical trials in the Olanzapine Integrated Database.</p><p><sup>11</sup>&nbsp;Adverse event identified from spontaneous post-marketing reporting with frequency determined utilising the Olanzapine Integrated Database.</p><p><sup>12</sup>&nbsp;Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database.</p><p><u>Long-term exposure (at least 48 weeks)</u></p><p>The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/LDL/HDL cholesterol or triglycerides increased over time. In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 6 months.</p><p><u>Additional information on special populations</u></p><p>In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see section 4.4). Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls. Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.</p><p>In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson&#39;s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.</p><p>In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels. Olanzapine administered with lithium or valproate resulted in increased levels (&ge;10%) of tremor, dry mouth (32% for olanzapine combination vs 9% for placebo), increased appetite (24% vs 8%), increased salivation (6% vs 2%), weight gain (26% vs 7%), dizziness (14% vs 7%), back pain (8% vs 4%), constipation (8% vs 4%). Speech disorder (7% vs 1%) was also reported commonly, amnesia (5% vs 2%), and paresthesia (5% vs 2%). During treatment with olanzapine in combination with lithium or divalproex, an increase of &ge; 7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks). Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of &ge;7% from baseline body weight in 39.9% of patients.</p><p><u>Paediatric population</u></p><p>Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years. Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.</p><p>The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients. Clinically significant weight gain (&ge; 7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures. The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The frequency terms listed are defined as follows: Very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p><p><em>Very common:</em>&nbsp;Weight gain<sup>13</sup>, elevated triglyceride levels<sup>14</sup>, increased appetite.</p><p><em>Common:</em>&nbsp;Elevated cholesterol levels<sup>15</sup>.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p><p><em>Very common:</em>&nbsp;Sedation (including: hypersomnia, lethargy, somnolence).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p><em>Common:</em>&nbsp;Dry mouth.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p><p><em>Very common:</em>&nbsp;Elevations of hepatic aminotransferases (ALT/AST; see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p><p><em>Very common:</em>&nbsp;Decreased total bilirubin, increased GGT, elevated plasma prolactin levels<sup>16</sup>.</p></td></tr></tbody></table><p><sup>13</sup>Following short-term treatment (median duration 22 days), weight gain &ge; 7% of baseline body weight (kg) was very common (40.6%); &ge; 15% of baseline body weight was common (7.1%) and &ge; 25% was common (2.5%). With long-term exposure (at least 24 weeks), 89.4% gained &ge; 7%, 55.3% gained &ge; 15% and 29.1% gained &ge; 25% of their baseline body weight.</p><p><sup>14</sup>Observed for fasting normal levels at baseline (&lt; 1.016 mmol/l) which increased to high (&ge; 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (&ge; 1.016 mmol/l - &lt; 1.467 mmol/l) to high (&ge; 1.467 mmol/l).</p><p><sup>15</sup>Changes in total fasting cholesterol levels from normal at baseline (&lt; 4.39 mmol/l) to high (&ge; 5.17 mmol/l) were observed commonly. Changes in total fasting cholesterol levels from borderline at baseline (&ge; 4.39 - &lt; 5.17 mmol/l) to high (&ge; 5.17 mmol/l) were very common.</p><p><sup>16</sup>Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.</p><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_13" o:spid="_x0000_s1026"
 style='position:absolute;margin-left:11.4pt;margin-top:12.4pt;width:453pt;
 height:138pt;z-index:251658240;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s)</strong></p><p>Saudi Arabia</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>Reporting Hotline:19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Signs and symptoms</u></em></p><p>Very common symptoms in overdose (&gt; 10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.</p><p>Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (&lt; 2% of overdose cases) and cardiopulmonary arrest. Fatal outcomes have been reported for acute overdoses as low as 450 mg but survival has also been reported following acute overdose of approximately 2 g of oral olanzapine.</p><p><em><u>Management </u></em></p><p>There is no specific antidote for olanzapine. Induction of emesis is not recommended. Standard procedures for management of overdose may be indicated (i.e. gastric lavage, administration of activated charcoal). The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60%.</p><p>Symptomatic treatment and monitoring of vital organ function should be instituted according to clinical presentation, including treatment of hypotension and circulatory collapse and support of respiratory function. Do not use epinephrine, dopamine, or other sympathomimetic agents with beta- agonist activity since beta stimulation may worsen hypotension. Cardiovascular monitoring is necessary to detect possible arrhythmias. Close medical supervision and monitoring should continue until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: diazepines, oxazepines and thiazepines, ATC code: N05A H03.</p><p><em><u>Pharmacodynamic effects</u></em></p><p>Olanzapine is an antipsychotic, antimanic and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems.</p><p>In preclinical studies, olanzapine exhibited a range of receptor affinities (K<sub>i</sub> &lt; 100 nM) for serotonin 5 HT<sub>2A/2C</sub>, 5 HT<sub>3</sub>, 5 HT<sub>6</sub>; dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>, D<sub>5</sub>; cholinergic muscarinic receptors M<sub>1</sub>-M<sub>5</sub>; &alpha;<sub>1</sub> adrenergic; and histamine H<sub>1</sub> receptors. Animal behavioural studies with olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor-binding profile. Olanzapine demonstrated a greater <em>in vitro </em>affinity for serotonin 5HT<sub>2</sub> than dopamine D<sub>2</sub> receptors and greater 5 HT<sub>2</sub> than D<sub>2</sub> activity <em>in vivo </em>models. Electrophysiological studies demonstrated that olanzapine selectively reduced the firing of mesolimbic (A10) dopaminergic neurons, while having little effect on the striatal (A9) pathways involved in motor function. Olanzapine reduced a conditioned avoidance response, a test indicative of antipsychotic activity, at doses below those producing catalepsy, an effect indicative of motor side-effects. Unlike some other antipsychotic agents, olanzapine increases responding in an &ldquo;anxiolytic&rdquo; test.</p><p>In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT<sub>2A</sub> than dopamine D<sub>2</sub> receptor occupancy. In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D<sub>2</sub> occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.</p><p><em><u>Clinical efficacy</u></em></p><p>In two of two placebo and two of three comparator controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.</p><p>In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p= 0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).</p><p>In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks. Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks. In a co- herapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.</p><p>In a 12-month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence. Olanzapine also showed a statistically significant advantage over placebo in terms of preventing either recurrence into mania or recurrence into depression.</p><p>In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0%, lithium 38.3%; p = 0.055).</p><p>In an 18-month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.</p><p><em><u>Paediatric population</u></em></p><p>The experience in adolescents (ages 13 to 17 years) is limited to short term efficacy data in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents. Olanzapine was used as a flexible dose starting with 2.5 and ranging up to 20 mg/day. During treatment with olanzapine, adolescents gained significantly more weight compared with adults. The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and prolactin (see sections 4.4 and 4.8) were greater in adolescents than in adults. There are no data on maintenance of effect and limited data on long term safety (see sections 4.4 and 4.8)<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption</u></em></p><p>Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5 to 8 hours. The absorption is not affected by food. Absolute oral bioavailability relative to intravenous administration has not been determined.</p><p><em><u>Distribution</u></em></p><p>The plasma protein binding of olanzapine was about 93 % over the concentration range of about 7 to about 1000 ng/ml. Olanzapine is bound predominantly to albumin and &alpha;1-acid-glycoprotein.</p><p><em><u>Biotransformation</u></em></p><p>Olanzapine is metabolized in the liver by conjugative and oxidative pathways. The major circulating metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier. Cytochromes P450- CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less <em>in vivo </em>pharmacological activity than olanzapine in animal studies. The predominant pharmacologic activity is from the parent olanzapine.</p><p><em><u>Elimination</u></em></p><p>After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects varied on the basis of age and gender.</p><p>In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/hr). The pharmacokinetic variability observed in the elderly is within the range for the non-elderly. In 44 patients with schizophrenia &gt; 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.</p><p>In female versus male subjects the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hrs) and the clearance was reduced (18.9 versus 27.3 l/hr). However, olanzapine (5-20 mg) demonstrated a comparable safety profile in female (n=467) as in male patients (n=869).</p><p>Hepatic impairment&nbsp;</p><p>A small study of the effect of impaired liver function in 6 subjects with clinically significant (Childs Pugh Classification A (n = 5) and B (n = 1)) cirrhosis revealed little effect on the pharmacokinetics of orally administered olanzapine (2.5 &ndash; 7.5 mg single dose): Subjects with mild to moderate hepatic dysfunction had slightly increased systemic clearance and faster elimination half-time compared to subjects with no hepatic dysfunction (n = 3). There were more smokers among subjects with cirrhosis (4/6; 67 %) than among subjects with no hepatic dysfunction (0/3; 0 %).</p><p><em><u>Renal impairment</u></em></p><p>In renally impaired patients (creatinine clearance &lt; 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr). A mass balance study showed that approximately 57 % of radiolabelled olanzapine appeared in urine, principally as metabolites.</p><p><em><u>Smokers</u></em></p><p>In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/hr, respectively).</p><p>In non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/hr).</p><p>The plasma clearance of olanzapine is lower in elderly versus young subjects, in females versus males, and in non-smokers versus smokers. However, the magnitude of the impact of age, gender, or smoking on olanzapine clearance and half-life is small in comparison to the overall variability between individuals.</p><p>In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.</p><p><em><u>Paediatric population</u></em></p><p>Adolescents (ages 13 to 17 years): The pharmacokinetics of olanzapine are similar between adolescents and adults. In clinical studies, the average olanzapine exposure was approximately 27% higher in adolescents. Demographic differences between the adolescents and adults include a lower average body weight and fewer adolescents were smokers. Such factors possibly contribute to the higher average exposure observed in adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Acute (single-dose) toxicity</u></em></p><p>Signs of oral toxicity in rodents were characteristic of potent neuroleptic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain. The median lethal doses were approximately 210 mg/kg (mice) and 175 mg/kg (rats). Dogs tolerated single oral doses up to 100 mg/kg without mortality. Clinical signs included sedation, ataxia, tremors, increased heart rate, labored respiration, miosis, and anorexia. In monkeys, single oral doses up to 100 mg/kg resulted in prostration and, at higher doses, semi-consciousness.</p><p><em><u>Repeated-dose toxicity</u></em></p><p>In studies up to 3 months duration in mice and up to 1 year in rats and dogs, the predominant effects were CNS depression, anticholinergic effects, and peripheral haematological disorders. Tolerance developed to the CNS depression. Growth parameters were decreased at high doses. Reversible effects consistent with elevated prolactin in rats included decreased weights of ovaries and uterus and morphologic changes in vaginal epithelium and in mammary gland.</p><p>Hematologic toxicity&nbsp;</p><p>Effects on hematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found. Reversible neutropenia, thrombocytopenia, or anemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [area under the curve] is 12- to 15-fold greater than that of a man given a 12 mg dose). In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow.</p><p><em><u>Reproductive toxicity</u></em></p><p>Olanzapine had no teratogenic effects. Sedation affected mating performance of male rats. Estrous cycles were affected at doses of 1.1 mg/kg (3 times the maximum human dose) and reproduction parameters were influenced in rats given 3 mg/kg (9 times the maximum human dose). In the offspring of rats given olanzapine, delays in fetal development and transient decreases in offspring activity levels were seen.</p><p><em><u>Mutagenicity</u></em></p><p>Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and <em>in vitro </em>and <em>in vivo </em>mammalian tests.</p><p><em><u>Carcinogenicity</u></em></p><p>Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Pearlitol SD 200</p></td></tr><tr><td><p>Prosolv SMCC 90</p></td></tr><tr><td><p>Aspartame NF</p></td></tr><tr><td><p>Hydroxypropyl cellulose Low-S</p></td></tr><tr><td><p>Crospovidone NF</p></td></tr><tr><td><p>Colloidal silicon dioxide</p></td></tr><tr><td><p>Magnesium Stearate</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Not applicable</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Reel AL/OPA/PVC Blister and Aluminium foil</p><p>Pack sizes:</p><p>Each pack contains 30 Oral Disintegrating tablets</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dammam Pharma
Saudi Arabia
Address: 1st industrial city, unit No.1, PO.BOX: 7137, Dammam 32234-4384
Phone: +966138216444
Fax: +966138216422
Email: regulatory-affairs@dammampharma.sa

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2019.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>